10月8日，嘉和生物-B(06998)盘中下跌13.68%，截至09:43，报2.02元/股，成交216.85万元。
嘉和生物药业是一家创新驱动型生物制药公司，主要打造了一个包括药物创新研发、临床前研究、临床开发、注册以及CMC开发的一体化平台，以治疗全球前三大肿瘤(乳腺癌、肺癌、胃肠道肿瘤)和血液肿瘤。公司拥有丰富的大分子药物开发经验，以及强大的分析检测能力和完备的质量体系，具备国际先进的工艺流程开发能力和临床前及临床用药生产能力。
截至2024年中报，嘉和生物-B营业总收入1447.0万元、净利润-1.26亿元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.